{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:18:59Z","timestamp":1740143939183,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","award":["SGZ201711942"],"award-info":[{"award-number":["SGZ201711942"]}],"id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11523-024-01043-2","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T15:02:47Z","timestamp":1709305367000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine\/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7397-1006","authenticated-orcid":false,"given":"Toshihiko","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Tsuduki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichinosuke","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"1043_CR1","first-page":"13","volume":"8","author":"A Patel","year":"2014","unstructured":"Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics. 2014;8:13\u201325.","journal-title":"Biologics"},{"key":"1043_CR2","doi-asserted-by":"crossref","unstructured":"Chiron M, Bagley RG, Pollard J, Henry C, Mankoo LV, Vincent L, et al. Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer. In: Proceedings of the 2013 AACR-NCI-EORTC International Conference on Molecular Targets. Mol Cancer Ther. 2013;12:11:Abstract B2.","DOI":"10.1158\/1535-7163.TARG-13-B2"},{"key":"1043_CR3","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarrulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"1043_CR4","doi-asserted-by":"crossref","unstructured":"Sims TN, Gao B, Chiron M, Mancini P, Bagley R, Lowy I. Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial. J Clin Oncol. 2015;33(3_Suppl.638).","DOI":"10.1200\/jco.2015.33.3_suppl.638"},{"key":"1043_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunama N, et al. Randomized trial of TAS\u2013102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319.","journal-title":"N Engl J Med"},{"key":"1043_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 2017;18:1172\u201381.","journal-title":"Lancet Oncol"},{"key":"1043_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S, Zitnjak D, Krogh M, Peterson LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412\u201320.","journal-title":"Lancet Oncol"},{"key":"1043_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100093","volume":"6","author":"T Takahashi","year":"2021","unstructured":"Takahashi T, Yamazaki K, Oki E, Shiozawa M, Mitsugi K, Makiyama A, et al. Phase II study of trifluridine\/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open. 2021;6: 100093.","journal-title":"ESMO Open."},{"key":"1043_CR9","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.21873\/anticanres.14988","volume":"41","author":"T Ishizaki","year":"2021","unstructured":"Ishizaki T, Mazaki J, Enomoto M, Shigoka M, Kasahara K, Matsudo T, et al. Prospective multicenter phase II study of biweekly TAS-102 and bevacizumab for metastatic colorectal cancer. Anticancer Res. 2021;41:2157\u201363.","journal-title":"Anticancer Res"},{"key":"1043_CR10","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","volume":"2512","author":"H Satake","year":"2020","unstructured":"Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, et al. Phase Ib\/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). Oncologist. 2020;2512:e1855\u201363.","journal-title":"Oncologist"},{"key":"1043_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10147-020-01794-8","volume":"26","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Yamada T, Kamiyama H, Kosugi C, Ishibashi K, Yoshida H, et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol. 2021;26:111\u20137.","journal-title":"Int J Clin Oncol"},{"key":"1043_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41416-023-02212-2","volume":"128","author":"Y Kuboki","year":"2023","unstructured":"Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, et al. Trifluridine\/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. Br J Cancer. 2023;128:1897\u2013905.","journal-title":"Br J Cancer"},{"key":"1043_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337\u201345.","journal-title":"N Engl J Med"},{"key":"1043_CR14","volume-title":"Statistical models and methods for lifetime data","author":"Lawless","year":"2003","unstructured":"Lawless, Jerald F. Statistical models and methods for lifetime data. 2nd ed. Manhattan: Wiley; 2003. (equation 4.1.5).","edition":"2"},{"key":"1043_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","volume":"27","author":"K Yamazaki","year":"2016","unstructured":"Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27:1539\u201346.","journal-title":"Ann Oncol"},{"key":"1043_CR16","doi-asserted-by":"publisher","first-page":"18702","DOI":"10.1002\/cam4.6486","volume":"12","author":"S Yuki","year":"2023","unstructured":"Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, et al. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: results from the GI-SCREEN CRC-Ukit study. Cancer Med. 2023;12:18702\u201316.","journal-title":"Cancer Med"},{"key":"1043_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1158\/1078-0432.CCR-19-1985","volume":"26","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Paccard C, Chiron M, Tabernero J. Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: biomarker post hoc analysis of the VELOUR trial. Clin Cancer Res. 2020;26:717\u201325.","journal-title":"Clin Cancer Res"},{"key":"1043_CR18","doi-asserted-by":"publisher","first-page":"57197","DOI":"10.18632\/oncotarget.11084","volume":"7","author":"L Alidzanovic","year":"2016","unstructured":"Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldoman A, Buchberger E, et al. The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. Oncotarget. 2016;7:57197\u2013212.","journal-title":"Oncotarget"},{"key":"1043_CR19","doi-asserted-by":"publisher","first-page":"S563","DOI":"10.1016\/j.annonc.2021.08.984","volume":"32","author":"S Yuki","year":"2021","unstructured":"Yuki S, Taniguchi H, Masuishi T, Shiozawa M, Bando H, Yamazaki K, et al. Impact of plasma angiogenesis factors on the efficacy of 2nd line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC); early efficacy results from GI SCREEN CRC Ukit study. Ann Oncol. 2021;32:S563\u20134.","journal-title":"Ann Oncol"},{"key":"1043_CR20","first-page":"419","volume":"2","author":"Y Kariya","year":"2022","unstructured":"Kariya Y, Kariya Y. Osteopontin in cancer: mechanisms and therapeutic targets. Int J Transl Med. 2022;2:419\u201347.","journal-title":"Int. J Transl Med."},{"key":"1043_CR21","doi-asserted-by":"publisher","first-page":"101042831986362","DOI":"10.1177\/1010428319863627","volume":"41","author":"M Assidi","year":"2019","unstructured":"Assidi M, Gomaa Y, Jafri M, Hanbazazh M, Al-Ahwal M, Pushparaj P, et al. Prognostic value of osteopontin (SPP1) in colorectal carcinoma requires a personalized molecular approach. Tumour Biol. 2019;41:1010428319863627.","journal-title":"Tumour Biol"},{"key":"1043_CR22","doi-asserted-by":"publisher","first-page":"12713","DOI":"10.1038\/srep12713","volume":"5","author":"M Zhao","year":"2015","unstructured":"Zhao M, Liang F, Zhang B, Yan W, Zhang J. The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis. Sci Rep. 2015;5:12713.","journal-title":"Sci Rep"},{"issue":"13","key":"1043_CR23","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3390\/cancers13153793","volume":"28","author":"K Amilca-Seba","year":"2021","unstructured":"Amilca-Seba K, Sabbah M, Larsen AK, Denis JA. Osteopontin as a regulator of colorectal cancer progression and its clinical applications. Cancers (Basel). 2021;28(13):3793.","journal-title":"Cancers (Basel)."},{"key":"1043_CR24","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1111\/cas.14198","volume":"110","author":"T Hamaguchi","year":"2019","unstructured":"Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, et al. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019;110:3565\u201372.","journal-title":"Cancer Sci"},{"key":"1043_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/ol.2017.6203","volume":"14","author":"H Kim","year":"2017","unstructured":"Kim H, Ahn ST, Kim JC, Bae SB, Kim HJ, Lee CS, et al. Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma. Oncol Lett. 2017;14:553\u201360.","journal-title":"Oncol Lett"},{"key":"1043_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/sj.bjc.6605925","volume":"103","author":"V Goede","year":"2010","unstructured":"Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010;103:1407\u201314.","journal-title":"Br J Cancer"},{"key":"1043_CR27","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1158\/1078-0432.CCR-07-0186","volume":"13","author":"NM Sorensen","year":"2007","unstructured":"Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res. 2007;13:4117\u201322.","journal-title":"Clin Cancer Res"},{"key":"1043_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1186\/s12885-018-4589-x","volume":"18","author":"C B\u00f6ckelman","year":"2018","unstructured":"B\u00f6ckelman C, Beilmann-Lehtonen I, Kaprio T, Koskensalo S, Tervahartiala T, Mustonen H, et al. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer. BMC Cancer. 2018;18:679.","journal-title":"BMC Cancer"},{"key":"1043_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11523-023-01027-8","volume":"19","author":"Y Sunakawa","year":"2024","unstructured":"Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, et al. Exploratory biomarker analysis using plasma angiogenesis-related factors and cell-free DNA in the TRUSTY study: a randomized, phase II\/III study of trifluridine\/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer. Target Oncol. 2024;19:59\u201369.","journal-title":"Target Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01043-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:51:48Z","timestamp":1711363908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01043-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01043-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"5 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Sanofi Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Toshihiko Matsumoto received research funding from Ono Pharmaceutical Co., Ltd and Sanofi Co., Ltd; honoraria from Bayer Co., Ltd, Bristol-Myers Squibb Co., Ltd, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Eli Lilly Japan Co., Ltd, Merck Bio Pharma Co., Ltd, MSD Co., Ltd, Ono Pharmaceutical Co., Ltd, Sanofi Co, Ltd, Taiho Pharmaceutical Co., Ltd, Takeda Co., Ltd, Teijin Pharmaceutical Co., Ltd, and Yakult Honsha Co., Ltd. Yoshiyuki Yamamoto received honoraria for lectures from Sanofi Co. Ltd, Ltd, Nihon Kayaku, Eisai, Bayer Co., Ltd, Lilly, Taiho Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Yakult Honsha Co., Ltd, Nihon Servier, Asahi Kasei, and Ono Pharmaceutical Co., Ltd. Masahito Kotaka has received payment or honoraria for lectures, presentations, speaker\u2019s bureau, manuscript writing, or educational events from Chugai Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co., Ltd, and Yakult Honsha Co., Ltd. Toshiki Masuishi has received institutional grants or contracts from MSD, Daiichi Sankyo Co., Ltd, Ono Pharmaceutical Co., Ltd, and Novartis and personal consulting fees from Takeda Pharma, Chugai Pharmaceutical Co. Ltd, Merck Biopharma, Taiho Pharmaceutical Co., Ltd, Bayer, Eli Lilly Japan, Yakult Honsha Co., Ltd, Sanofi Co. Ltd, Daiichi Sankyo Co., Ltd, Ono Pharmaceutical Co., Ltd, and Bristol Myers Squibb. Hirokazu Shoji has received honoraria from Ono Pharmaceutical Co., Ltd and Zymeworks Inc.; has been on advisory boards for Personal Amgen, Astellas, Daiichi Sankyo Co., Ltd, MSD, and Takeda Pharma; and a local PI. Akitaka Makiyama has received honoraria from Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co. Ltd., and Daiichi Sankyo Co. Ltd. Naoki Takahashi has received honoraria from Ono Pharmaceutical Co, Ltd, Taiho Pharmaceutical Co. Ltd, and Bristol Myers Squibb. Takashi Ohta has received honoraria from Eli Lilly, Bristol-Myers Squibb K.K., Taiho Pharmaceutical Co. Ltd, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd, and Merck & Co., Inc. Yosuke Kito has received honoraria from Taiho Pharmaceutical Co. Ltd, Ono Pharmaceutical Co., Ltd, and Daiichi Sankyo Co., Ltd. Narikazu Boku has received lecture fees or honoraria from Bristol-Myers Squibb, Daiichi-Sankyo Co., Ltd, Ono Pharmaceutical Co., Ltd, and Taiho Pharmaceutical Co. Ltd, and research funds from Ono Pharmaceutical Co., Ltd and Takeda. Kentaro Yamazaki has received honoraria for lectures from Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Daiichi Sankyo Co., Ltd., Merck Biopharma Co., Ltd., Sanofi K.K., MSD K.K., Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. Shuichi Hironaka has received lecture fees or honoraria from Taiho Pharmaceutical Co., Ltd. Kei Muro has received lecture fees or honoraria from Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Takeda Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd, and Taiho Pharmaceutical Co. Ltd; research funds from Chugai Pharmaceutical Co., Ltd., MSD K.K., Amgen K.K., Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc., Sanofi Co., Ltd., Taiho Pharmaceutical Co. Ltd., Eisai Co., Ltd., Daiichi-Sankyo Co. Ltd., Novartis Pharma K.K., and Pfizer Japan Inc., and has been an advisor for AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., and Amgen K.K. Yasushi Tsuji, Kenro Hirata, Takao Tsuduki, Naoki Izawa, Masahiro Tsuda, Hisateru Yasui, Satoshi Otsu, Ichinosuke Hyodo, and Kenichi Yoshimura have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved by the certified Review Board of Aichi Cancer Center Hospital and has been registered in the Japan Registry of Clinical Trials (jRCTs041190100).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all patients before study enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study concept\u2014TM, KY, and KM. Study design\u2014TM, KY and KM. Acquisition, analysis, or interpretation of data\u2014All authors. Statistical analysis\u2014NI and KY. Manuscript preparation\u2014TM, NI, SH, NB and IH. Manuscript editing and revision\u2014All authors. Manuscript review and approval\u2014All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}